Quell Therapeutics announced that QEL-005, its CD19 B-cell activated Phenotype-Locked™ engineered nTreg therapy, has advanced to the second planned dose cohort in the CHILL Phase 1/2 clinical study.
NRG Therapeutics announced a positron emission tomography (PET) imaging trial (NRG5051-102) to assess the biodistribution of its lead clinical asset NRG5051 has started.
Chris Molloy on investment in dementia; AI in healthcare; TechBio; BioJapan; bioProcessUK; Green, Conservative and Labour conferences; and BIA Board elections
Cancer Research UK have signed an agreement with ORIC Pharmaceuticals, Inc. to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into clinical development.
Aravax announces it will be communicating topline results from its Phase 2 study of its lead product, PVX108 for the treatment of peanut allergy, at major conferences in the US and Europe in November 2026
Tangram Therapeutics announces progression to patient cohorts in Phase 1/2 RESTORE-MASH trial of TGM-312 and appointment of Dr Sonya Montgomery as Chief Development Officer
Initial data show that a single dose of APL-10456 was well-tolerated, highly immunogenic, and induced Th1-polarized broad cross-rhinovirus species cellular immunity.
Chris Molloy on Mike Hoare, the RedX-Skye deal, Stablepharma’s fridge-free vaccine, MHRA quarterly numbers, ministerial responsibilities for UK life sciences and human biology-based models
Chris Molloy on new pension scale-up fund news, member news from Touchlight, the major GSK investment in Cambridge, a valuable collaboration for Relation and BIA's parliamentary engagement
tranScrip recently hosted its Ask the Experts Live Q&A: From Preclinical to First-in-Human. If you couldn't join us live, the full recording is now available to watch on demand at your convenience.
The UK’s innovative life sciences sector has called on Government to deliver policy continuity, unlock scale-up investment and improve patient access to new medicines.
Epitopea announced that it has received approval from MHRA and the REC for its clinical trial application (CTA) for its first-in-human clinical trial (OVACT) of CryptiVax™-1001.
The UK BioIndustry Association (BIA) is the UK’s trade association for innovative life sciences and the leading UK-wide forum for expert communities and high quality peer-to-peer networking in the sector.
